Biogen climbs after quarterly profit beat

Biogen

29/04/2026 11:34

** Shares of drugmaker Biogen rise 3.6% to $190.01 premarket

** Co reports Q1 adj. profit of $3.57/shr vs analysts' average estimate of $2.77/shr - LSEG data

** BIIB's quarterly revenue of $2.48 billion beats analysts' average expectation of $2.26 billion, helped by better-than-expected sales of its multiple sclerosis drugs

** Co lowers annual adjusted profit forecast to between $14.25 and $15.25 per share from a range of $15.25 to $16.25, on acquisition-related costs

** Up to last close, stock up 4.2% YTD

 (Reporting by Christy Santhosh)

 ((Christy.Santhosh@thomsonreuters.com))